Smartphone-based home screening significantly boosts chronic kidney disease (CKD) diagnosis and follow-up care, enhancing ...

S.F. Holding Co., Ltd. (002352.SZ; 06936.HK, 'SF Holding', 'SF' or the 'the Company') announced a USD 376 million H-share equity placement and concurrent USD 376 million offering of 363-day ...

Background and objective Diabetes is a strong risk factor for cardiovascular diseases, whereas few studies have investigated simultaneously the associations of glycated haemoglobin A1c (HbA1c), ...

The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted BioCity's ...

BioCity Biopharma ("BioCity") announced today that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to ...

The Magmaris bioresorbable scaffold was associated with a high restenosis rate 5 years into the MAGSTEMI trial, so a new ...

Albuminuria: Albuminuria is present in ≈9.5% of US adults. 67: Albuminuria is strongly and independently associated with multiple adverse outcomes, including death, cardiovascular events, and kidney ...

Lorundrostat shows promise in reducing blood pressure and proteinuria in patients with hypertension and chronic kidney ...

A smartphone-based home albuminuria test facilitates screening and early diagnosis of kidney disease in high-risk individuals ...

This Phase 2 trial was designed to evaluate BP reduction and safety of 25 mg QD lorundrostat when added to background treatment with an ACEi or ARB and an SGLT2 inhibitor for the treatment of ...